JavaScript is disabled. Please enable to continue!
Services >> Efficacy >> Inflammation

Inflammation / Allergy Services

Sidebar Image

Preclinical evaluation of suppression of immunological and inflammatory responses 

Eurofins Pharma Discovery Services has 30 years of experience creating and working with a diverse set of in vivo efficacy models for inflammatory diseases.  These models range from basic models of immune modulation, restoration, suppression and stimulation to specific models of inflammation-induced organ damage.  All experimental models are tested in a dose-dependent manner with approved benchmark positive controls.

The ability for Eurofins to deliver multi-faceted outcome studies, means that you will receive the data that is most appropriate for your program.  We routinely measure relevant biomarkers (e.g., cytokines) employing our highly sensitive ImmunoSignal™ services; physiologic outcomes, like airway hyper responsiveness, and swelling; as well as more complex behavioral outcome measures such as scratching or mechanical allodynia or histopathology.

Rely on Eurofins to deliver the most meaningful preclinical data, allowing you to decide whether your candidates' efficacy meets the criteria for full clinical development.

Advantages of preclinical inflammation / allergy studies with Eurofins:

  • >30 therapeutically relevant models, including:
    • Collagen (CIA) or adjuvant (AIA) induced arthritis
    • Colitis
    • Pulmonary inflammation
    • Allergic reaction
    • Allergic/irritant contact or atopic dermatitis
    • Septic shock - LPS-induced or cecal ligation and puncture
    • Wound healing
    • Pancreatitis
    • Fibrosis - pulmonary, hepatic or renal
  • Models are qualified in a dose-dependent manner with approved benchmark positive controls
  • Experienced running combination studies
  • Companion services can monitor blood or organ exposure and biomarker analysis for PK/PD assessment